TOFATOP XR TAB

About

Tofatop XR Tablet typically contains Tofacitinib, an oral Janus kinase (JAK) inhibitor. Tofacitinib works by selectively inhibiting the activity of JAK enzymes, which are intracellular enzymes involved in signaling pathways that mediate the immune response and inflammation. By blocking JAK pathways, particularly JAK1 and JAK3, Tofacitinib interferes with the signaling of various cytokines and growth factors that contribute to the pathogenesis of autoimmune and inflammatory diseases.

The extended-release (XR) formulation allows for once-daily dosing, providing sustained therapeutic levels of the drug and improving patient adherence. It is primarily used in the treatment of chronic inflammatory conditions where conventional therapies have been insufficient or poorly tolerated. Its targeted mechanism of action helps to reduce inflammation, alleviate symptoms, and slow disease progression in conditions characterized by dysregulated immune responses.

Uses

• Treatment of rheumatoid arthritis
• Management of psoriatic arthritis
• Therapy for ulcerative colitis
• Treatment of ankylosing spondylitis

Directions For Use

Take one tablet orally once daily, with or without food, as directed by your physician. Swallow the tablet whole; do not crush, cut, or chew.

Benefits

• Reduces joint pain and swelling
• Improves physical function
• Slows disease progression in autoimmune conditions
• Provides sustained symptom control
• Convenient once-daily dosing
• Effective in patients unresponsive to other therapies

Side Effects

• Upper respiratory tract infections
• Headache
• Diarrhea
• Nausea
• Nasopharyngitis
• Increased cholesterol levels
• Anemia
• Herpes zoster reactivation
• Urinary tract infections
• Increased risk of serious infections
• Lymphopenia
• Neutropenia

Safety Measures

• Alcohol - No direct interaction with alcohol, but excessive alcohol consumption can exacerbate liver issues, which should be monitored with Tofacitinib.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Use effective contraception during treatment and for at least 4 weeks after the last dose.
• Breastfeeding - Tofacitinib is excreted in breast milk. Breastfeeding is not recommended during treatment and for at least 18 hours after the last dose.
• Liver - Use with caution in patients with moderate to severe liver impairment. Dose adjustment may be necessary, and liver function should be monitored.
• Kidney - Dose adjustment is required in patients with moderate to severe renal impairment. Renal function should be monitored regularly.
• Lung - Use with caution in patients with pre-existing lung conditions, as there have been reports of interstitial lung disease with JAK inhibitors.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.